Okay, so we investigated whether a variable rhythm monitoring strategy in patients after ischemic stroke leads to a comparable probability of AF detection compared to the current reference standard, the implantable cardiac monitor. And we included 84 patients with ischemic stroke, which were already randomized in a larger trial, the FIND-AF2 trial, which investigates whether an enhanced, prolonged, and intensified rhythm monitoring leads to a reduction of recurrent stroke or systemic embolism...
Okay, so we investigated whether a variable rhythm monitoring strategy in patients after ischemic stroke leads to a comparable probability of AF detection compared to the current reference standard, the implantable cardiac monitor. And we included 84 patients with ischemic stroke, which were already randomized in a larger trial, the FIND-AF2 trial, which investigates whether an enhanced, prolonged, and intensified rhythm monitoring leads to a reduction of recurrent stroke or systemic embolism. And patients in the intervention arm with high-risk for AF were provided with an implantable cardiac monitor and this was the perfect opportunity to test the performance of variable against the current reference standard already in place. And patients were randomized one-to-one to either an Apple Watch Series 10 or the pulse-on arrhythmia monitoring system from Finland. And they were provided with the devices for 12 weeks and continued ICM monitoring throughout the study. And patients, we combined two strategies, photoplethysmography or optical pulse monitoring together with patient-recorded ECGs and patients were asked to record ECGs twice daily at 10 in the morning and 6 in the evening and whenever rhythm alerts occurred. The Apple watch used visual reminders and alerts and the pulse-on device used vibration. And the Apple watch was paired with an iPhone. Both devices had to be paired with an iPhone. Both devices had to be charged daily, while the Pulse On system had to be charged once a week. And our results, we included a stroke population approximately 75 years old. 40 patients were assigned to the Apple Watch arm and 43 to the Pulse On arm. The ICMs in these patients were implanted approximately two years ago, and some patients already had atrial fibrillation, which were less in the Apple Watch arm than in the Pulse On arm by randomization. And we detected atrial fibrillation during the study period with the implantable cardiac monitor in seven patients in the Apple Watch arm and 15 in the PulseOn arm. And what we’ve seen for our primary endpoint, which was the sensitivity as a function of atrial fibrillation duration, we’ve seen that the detection of atrial fibrillation was strongly episode duration dependent. Shorter episodes were frequently missed by both devices, while longer episodes enhanced the probability of atrial fibrillation detection, which reached nearly 100% in episodes lasting 24 hours or longer. And this was nearly the same result for both devices, and there was no statistical difference. And our secondary endpoint was the overall sensitivity, and there we’ve seen that the Apple Watch found atrial fibrillation in five out of seven patients, missed two. One of them had a very short AF episode and one did not perform ECGs for four weeks where the AF episode happened. And PulseOn found 14 out of 15 patients and the one patient who was missed retracted his study consent early and was therefore missed because he did not transmit variable data at all. And there was a difference of 22 percent towards PulseOn but this was not statistically significant. And both devices had a good monitoring coverage which was higher in PulseOn which was statistically significant. Maybe it’s because the device had to be charged only once a week compared to the Apple Watch, which has to be charged daily.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.